Masimo believes a smart age requires smart medical tests

January 08th, 2008 | Category: Stocks to Buy

Readers of that space know that the investment bias is toward large-cap companies with demonstrated commerce models and who have a competitive advantage in established markets, preferably with a favorable global trend as a support. But every once in while an exception is made for a smaller, innovative company, and along that line Masimo looks appealing.

Masimo Corporation (Nasdaq: MASI)’s sign extraction technology non-invasively monitors patients’ arterial blood-oxygen saturation levels and pulse rates.

Analysts like

MASI’s product variation, which features pulse oximeters in both hand-held and stand-alone versions, and the company’s client diversity: MASI has sold products to more than 35 medical equipment companies. The Reuters FY 2007/FY 2008 EPS consensus estimates for MASI are $0.66 to $0.50.

Continue reading Masimo believes a smart age requires smart medical tests

Original post by Joseph Lazzaro

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.